Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer-Reference-Cited by-同舟云学术

Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer

Published:2020-12-14 Issue: Volume: Page:
ISSN:1465-1858
Container-title:Cochrane Database of Systematic Reviews
language:en
Short-container-title:

Author:

Ferrara Roberto¹,Imbimbo Martina²,Malouf Reem³,Paget-Bailly Sophie⁴⁵,Calais François⁶,Marchal Corynne⁷,Westeel Virginie⁴⁸⁹

Affiliation:

1. Thoracic Oncology Unit; Fondazione IRCSS Istituto Nazionale dei Tumori; Milano Italy

2. Department of Oncology; Lausanne University Hospital, and Ludwig Institute for Cancer Research, University of Lausanne; Lausanne Switzerland

3. National Perinatal Epidemiology Unit (NPEU); University of Oxford; Oxford UK

4. Methodological and Quality of Life in Oncology Unit; University Hospital of Besançon; Besançon France

5. Université de Franche-Comté, INSERM, EFS BFC, UMR 1098, Interactions Hôte-Greffon-Tumeur/Ingénierie Cellulaire et Génique, Besançon, France; Besançon France

6. Bibliothèque universitaire de Santé; Université de Franche-Comté; Besançon France

7. Université de Franche-Comté; Besançon France

8. Department of Thoracic Oncology; University Hospital of Besançon; Besançon France

9. Université Bourgogne Franche-Comté, INSERM, EFS BFC, UMR 1098, Interactions Hôte-Greffon-Tumeur/Ingénierie Cellulaire et Génique; Besançon France

Publisher

Wiley

Subject

Pharmacology (medical)

Reference101 articles.

1. First-line nivolumab in stage IV or recurrent non-small-cell lung cancer;Carbone;New England Journal of Medicine,2017

2. An open-label, randomized, phase 3 trial of nivolumab versus investigator's choice chemotherapy as first-line therapy for stage IV or recurrent PD-L1+ non-small cell lung cancer (CheckMate 026) https://clinicaltrials.gov/ct2/show/NCT02041533

3. CheckMate 227: patient-reported outcomes of first-line nivolumab + ipilimumab in high tumor mutational burden advanced NSCLC;Brahmer;Journal of Thoracic Oncology,2018

4. Nivolumab plus ipilimumab in lung cancer with a high tumor mutational burden;Hellmann;New England Journal of Medicine

5. Nivolumab plus ipilimumab in advanced non-small-cell lung cancer;Hellmann;New England Journal of Medicine,2019

Cited by 45 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Renin–angiotensin–aldosterone system inhibitors are associated with improved paclitaxel-induced peripheral neuropathy in lung cancer: a study using administrative claims data;Supportive Care in Cancer;2023-11-29

2. Association of renin–angiotensin–aldosterone system inhibitors with paclitaxel-induced peripheral neuropathy;2023-07-21

3. Research progress of biomarkers in the prediction of anti-PD-1/PD-L1 immunotherapeutic efficiency in lung cancer;Frontiers in Immunology;2023-07-03

4. Potential Applications of Nanoparticles in Improving the Outcome of Lung Cancer Treatment;Genes;2023-06-28

5. Severe and fatal adverse events of immune checkpoint inhibitor combination therapy in patients with metastatic renal cell carcinoma: a systematic review and meta-analysis;Frontiers in Immunology;2023-06-19